Related Experiment Videos
Enzyme immunoassay for myelin basic protein in cerebrospinal fluid
F Najeme1, J Julien, S Herblot
1Laboratoire d'Immunologie Moléculaire, Bâtiment 1b-Carreire Nord, Université de Bordeaux II, France.
Brain Research. Brain Research Protocols
|May 1, 1997
Summary
A new enzyme immunoassay (EIA) accurately measures myelin basic proteins (MBPs) in cerebrospinal fluid (CSF). This method offers a sensitive, radioactivity-free alternative to radioimmunoassay (RIA) for diagnosing demyelinating diseases like multiple sclerosis (MS).
Area of Science:
- Neuroscience
- Immunology
- Biochemistry
Background:
- Myelin basic proteins (MBPs) are crucial components of central nervous system myelin.
- MBPs are extensively used to model multiple sclerosis (MS) through experimental allergic encephalomyelitis (EAE) in animals.
- MBP concentration in cerebrospinal fluid (CSF) serves as a key biomarker for demyelinating conditions.
Purpose of the Study:
- To develop a novel enzyme immunoassay (EIA) for quantifying MBP levels.
- To provide a sensitive and stable alternative to radioimmunoassay (RIA) for MBP detection.
Main Methods:
- Development of a new enzyme immunoassay (EIA) technique.
- Utilized enzyme-labelled MBP tracer for detection.
- Validated sensitivity and sample volume requirements.
Main Results:
- The developed EIA exhibits comparable sensitivity to RIA (0.1-2.5 ng/ml).
- The EIA requires only small CSF volumes (50 microliters).
- The enzyme-labelled MBP tracer demonstrates stability for over 12 months.
Conclusions:
- The new EIA is a highly sensitive, practical, and stable method for measuring MBP in CSF.
- This assay offers a valuable, radioactivity-free tool for diagnosing and monitoring demyelinating diseases such as MS.